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Background: Changes in structural and functional central nervous system have 
been reported in narcolepsy, with large discrepancies between studies. No study has 
investigated yet spontaneous brain activity at wake in idiopathic hypersomnia (IH). 
We compared relative changes in regional brain metabolism in two central hypersomnia 
conditions with different clinical features, namely narcolepsy type 1 (NT1) and IH, and in 
healthy controls.
Methods: Sixteen patients [12 males, median age 30  years (17–78)] with NT1, nine 
patients [2 males, median age 27  years (20–60)] with IH and 19 healthy controls 
[16 males, median age 36 years (17–78)] were included. 18F-fludeoxyglucose positron 
emission tomography (PET) was performed in all drug-free subjects under similar condi-
tions and instructions to stay in a wake resting state.
results: We found increased metabolism in the anterior and middle cingulate and the 
insula in the two pathological conditions as compared to healthy controls. The reverse 
contrast failed to evidence hypometabolism in patients vs. controls. Comparisons 
between patient groups were non-significant. At sub-statistical threshold, we found 
higher right superior occipital gyrus glucose metabolism in narcolepsy and higher middle 
orbital cortex and supplementary motor area metabolism in IH, findings that require 
further confirmation.
conclusion: There is significant hypermetabolism in narcolepsy and IH in the wake 
resting state in a set of brain regions constitutive of the salience cortical network that 
may reflect a compensatory neurocircuitry activity secondary to sleepiness. Metabolic 
differences between the two disorders within the executive-control network may be 
a signature of abnormally functioning neural system leading to persistent drowsiness 
typical of IH.
Keywords: narcolepsy, idiopathic hypersomnia, metabolism, positron emission tomography, imaging, salience 
network, default mode network, executive-control network
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inTrODUcTiOn
In the past few decades, neuroimaging studies have significantly 
contributed to our understanding of sleep physiology and sleep 
disorders in humans (1). Changes in structural and functional 
central nervous system have been reported in central hyper-
somnia disorders and especially in narcolepsy (2–6). However, 
results are inconsistent with either increased or decreased 
relative regional metabolism and perfusion in particular areas. 
For instance, a 18F-fludeoxyglucose (FDG) positron emission 
tomography (PET) study reported reduced metabolism in nar-
colepsy in a wide set of cortico-subcortical areas including the 
bilateral rectal and subcallosal gyri, the right superior frontal 
gyrus and inferior parietal lobule, the left supramarginal gyrus, 
the precuneus bilaterally, and the posterior hypothalamus and 
mediodorsal thalamic nuclei (3). Using a similar procedure, we 
found, on the opposite, increased metabolism in the anterior and 
mid-cingulate cortex, the cuneus, and the lingual gyrus in drug-
free patients with narcolepsy–cataplexy scanned in a fully awake 
condition (2). A more recent PET study found hypometabolism 
in the right mid-frontal lobe and angular gyrus in young type 1 
narcoleptic patients and hypermetabolism in the hippocampus, 
parahippocampus, amygdala, fusiform, left inferior parietal lobe, 
left superior temporal lobe, striatum, basal ganglia and thalamus, 
right hypothalamus, and pons (6). Discrepancies between studies 
might be partially explained by differences between populations 
[controls and patients’ phenotype, narcolepsy type 1 (NT1) vs. 
2, etc.], drug-free vs. treatment conditions, age and disease dura-
tion, sample size, procedure and scanning methods, and statisti-
cal analyses. However, we may also hypothesize that most of these 
differences actually relate to a dissimilar vigilance status during 
the imaging sessions (i.e., awake vs. drowsy vs. sleepy).
Spontaneous ensembles of brain activity in the resting state 
are classically categorized between three major networks accord-
ing to their underlying neuroanatomy and functions: (1) the 
default-mode network that relates to internally oriented thoughts 
and whose major node is the posterior cingulate cortex, (2) the 
salience network linking the detection of behaviorally relevant 
stimuli and the coordination of neural resources, mostly associ-
ated with the anterior cingulate and insular cortices nodes, and 
(3) the executive-control network that relates to externally guided 
awareness, linked with dorsal lateral prefrontal cortex and pre-
cuneus nodes (7–10). Considering in this framework, the results 
of the three aforementioned studies (2, 3, 6), patients with NT1 
may exhibit decreased activity in part of the executive-control 
network and/or increased activity in part of the salience network. 
Importantly, relative hyper- or hypometabolism might be contin-
gent upon the conditions and instructions given to the subjects at 
the time of PET scanning, more than to the development of the 
disorder in itself and/or the consequences of the sleep pathology.
Narcolepsy type 1 is the most severe cause of daytime sleepi-
ness in humans, associated with cataplexy, frequent disrupted 
nighttime sleep, hypnagogic hallucinations and sleep paralysis, 
with recent insights demonstrating selective and irreversible 
loss of hypothalamic hypocretin neurons (11, 12). Idiopathic 
hypersomnia (IH) is another orphan central hypersomnolence 
disorder, with no identified biomarkers so far (13). Management 
strategies for hypersomnolence are rather codified for both dis-
orders with first-line medication being modafinil, with potential 
for innovative emerging therapies in the next few years (14–16).
To the best of our knowledge, no study has yet investigated 
spontaneous brain activity in the resting awake state in IH. Since 
activation and deactivation of particular central neural pathways 
are reported across different vigilance states (17), we compared 
intrinsic neural activity in the wake state using 18FDG PET-scan 
under similar instructions and conditions in drug-free patients 
with NT1 or with IH, and in healthy controls. Considering that 
hypersomnolence is a shared symptom in narcolepsy and IH, 
leading to higher demands to maintain a wake state, we hypoth-
esized that fluctuations of brain’s intrinsic activity in patients 
might reflect the involvement of the neurocircuitry underlying 
sleepiness in the two pathological conditions, rather than a spe-
cific feature of the underlying disorder itself (e.g., the hypocretin 
deficiency for NT1). In other terms, patients with either NT1 or 
IH may exhibit significant brain metabolism differences in com-
parison to healthy controls, but with limited differences between 
the two patient groups.
MaTerials anD MeThODs
Participants
Sixteen drug-free patients [12 males and 4 females, median age 
30 years (range 17–78)] with NT1, clear-cut cataplexy, positive 
HLA DQB1*06:02 typing were included. All patients complained 
of constant EDS (Score on Epworth Sleepiness Scale >10/24). 
All patients had ≥2 sleep onset REM periods (SOREMPs) and 15 
had mean sleep latency <8 min on the multiple sleep latency test. 
All had low CSF hypocretin-1 level (<110 pg/ml). Seven drug-
free patients with NT1 were already included in our previous PET 
scan study (2).
Nine drug-free patients [2 males and 7 females, median age 
27  years (range 20–60)] affected with IH according to ICSD-3 
criteria were included (18). All patients complained of constant 
excessive daytime sleepiness (Score on Epworth Sleepiness 
Scale >10/24), non-refreshing naps irrespective of duration, 
uninterrupted and prolonged nighttime sleep (>10 h asleep per 
night), and sleep inertia. Six patients reported onset age during 
adolescence. Patients were asked to practice good sleep hygiene 
and to complete a sleep diary during the week before PSG record-
ing to avoid sleep deprivation and large variations in sleep onset 
and offset. Six patients had mean sleep latency <8 min on the 
MSLT, of whom one had one SOREMP and none had two or more 
SOREMPs. All patients underwent a prolonged continuous PSG 
recording showing a total sleep time >11/24 h for eight patients. 
Sleep efficiency on the PSG was >90%, with a respiratory event 
index (apneas + hypopneas) <10/h, periodic leg movement index 
during sleep <10/h, microarousal index <10/h, and normal 
percentages of slow wave and REM sleep. CSF lumbar puncture 
was performed in all cases and all had normal hypocretin-1 level 
(>200 pg/ml).
As controls, 19 healthy subjects [16 males and 3 females, median 
age 36 years (range 17–78)] participated in the study. All controls 
had normal clinical neurological examination, normal and regular 
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sleep, no sleepiness complaint, no hallucinations, no sleep paraly-
sis, normal body mass index, and were free of any treatment that 
may interfere with sleep, motor, or psychological functions.
None of the participants had any psychiatric disorder (espe-
cially depression) based on the DSM-V criteria (19). Patients 
were not taking psychostimulant medications or any other 
medications known to influence sleep ≥2  weeks prior to sleep 
recording and 18FDG-PET scanning.
All participants gave their written informed consent to 
participate in this study approved by the Montpellier University 
Hospital’s ethics committee.
PeT Procedure and Data acquisition
All subjects (patients and controls) received via intravenous 
line an injection of 2.5 MBq/kg of FDG, between 10:30 a.m. and 
12:30 a.m. Before the injection, subjects were comfortably seated 
in a quiet, isolated room and asked to keep eyes closed to avoid 
noxious, auditory, or visual stimuli, for durations of 5–10 min. 
Up to PET scan acquisition, patients and controls were asked to 
remain fully awake, to not move or talk, under the supervision 
of both a neurologist and a technician during the whole process. 
None of the subjects slept before the injection and during the 
PET scan acquisition as assessed by questioning the subject after 
the procedure. The vigilance state of patients and controls was 
also supervised clinically and by video by both a neurologist 
(Elisa Evangelista and Yves Dauvilliers) and a technician during 
the whole process. In addition, we controlled for the absence of 
emotional triggering factors during the entire process to avoid 
cataplexy-related episodes.
Positron emission tomography images were acquired 30 min 
after injection, during 15  min with a PET scanner Siemens 
mCT20 Flow. The volume was reconstructed using an iterative 
reconstruction (TrueX + TOF ultraHD PET with 8 iterations and 
21 subsets, Gaussian 2 and zoom 2), following the manufacturer’s 
operating instructions. The resulting images contained 109 con-
tiguous slices with a plane separation of 2 mm.
statistical analyses
Categorical variables for the sample are presented as percentages, 
and quantitative variables as medians with range. Most distribu-
tions were skewed according to Shapiro–Wilks test. Skewed 
distributions between groups were compared using the Kruskal–
Wallis test (multiple-group comparisons). Chi-square or Fisher’s 
tests were used to compare categorical variables between groups. 
When comparisons among the three groups were statistically 
significant, two-by-two comparisons were conducted with a 
multiple comparisons correction using the Bonferroni method.
Metabolic data were analyzed using SPM8 software (Wellcome 
Department of Cognitive Neurology, Institute of Neurology, 
London, UK) implemented in MATLAB (Mathworks, Sherborn, 
MA, USA). Images were spatially normalized into the ICBM 
standard space using 2nd degree B-spline interpolations, and 
smoothed using a 16-mm full-width half-maximum isotropic 
Gaussian kernel.
Areas of significant relative (instead of absolute) change 
between the groups (i.e., Narcolepsy, IH, and Controls) were 
estimated according to the general linear model using linear 
contrasts (14). Global metabolism adjustment was performed 
using proportional scaling. Main contrasts estimated the main 
effect of pathology [controls vs. narcolepsy; controls vs. IH] 
to identify the brain regions where glucose metabolism was 
decreased (or increased) in pathological populations as compared 
to the controls cohort. In a second step, the condition effects were 
assessed within the pathological populations (narcolepsy vs. IH) 
to identify brain areas where glucose metabolism was higher 
(or lower) as a function of the disease type. Given the extended age 
range in our populations (18–78 years), age was entered as a con-
founding covariate in all analyses. The resulting set of voxel values 
for each contrast constituted a map of the T statistics [SPM{T}], 
thresholded at punc ≤ 0.001 (T ≥ 3.35; uncorrected for multiple 
comparisons) or pcorr < 0.05 (corrected for multiple comparisons) 
in contrast between patient groups (narcolepsy or hypersomnia) 
and controls. Direct comparisons between pathological condi-
tions were thresholded at exploratory level punc ≤ 0.05 (T ≥ 1.71; 
uncorrected). In all contrasts, minimal spatial extent for reported 
brain areas is 50 contiguous significant voxels. Previously used 
(20) liberal statistical thresholds (punc < 0.05) for the direct com-
parison between pathological conditions are justified by reduced 
sample size and variability in each subpopulation.
resUlTs
Population
Demographic and sleep characteristics of patients with NT1, IH, 
and controls are summarized in Table 1 with statistics. Between-
group gender differences were found: patients with narcolepsy 
and healthy controls were more likely to be men, and IH to be 
women. No significant between-group differences were found 
for age at time of study, age at onset of EDS, ESS, and body mass 
index. The mean sleep latency and the number of SOREMPs on 
the MSLT differed between patient groups as expected.
cerebral glucose Metabolism in Patients 
with nT1 and ih vs. healthy controls
In patients with narcolepsy as compared to healthy controls, 
regional glucose metabolism in the fully awake condition 
increased in the left rolandic operculum (pcorr < 0.05), and in the 
bilateral middle cingulate and fusiform regions, insula, and right 
temporal lobes (punc < 0.001; see Table 2 and Figure 1). No hypo-
metabolism was found in patients with narcolepsy as compared 
to controls.
In patients with IH as compared to healthy controls, brain 
regional metabolism in the fully awake condition increased in the 
insula and in the right caudate nucleus (pcorr < 0.05), and in the 
middle and anterior cingulate cortices (punc <  0.001; Table  2; 
Figure 1). Also in this population, no hypometabolism was found 
as compared to controls.
cerebral glucose Metabolism in Patients 
with nT1 vs. ih
Comparisons between patient groups were non-significant. 
However, slight between-groups differences were evidenced at 
conventional uncorrected statistical threshold (punc < 0.001), with 
FigUre 1 | Regional cerebral increases in patients with narcolepsy type 1 
(red) and idiopathic hypersomnia (IH) (green), as compared to healthy 
controls, superimposed on a template T1-weighted magnetic resonance 
image (MRI). Activations are displayed at punc < 0.001 uncorrected threshold, 
for clusters >50 voxels. Yellow clusters are area of similar hypermetabolism 
[insula (Ins) and middle cingulate (Cg); see arrows] in narcolepsy and IH as 
compared to controls.
TaBle 2 | Statistical parametric mapping results of brain regions showing 
relative metabolism changes in patients with narcolepsy type 1 (A) and idiopathic 
hypersomnia (IH) (B), as compared to healthy controls.
hemisphere coordinates Z-score
(l)eft/(r)ight x y z
(a) narcolepsy vs. healthy controls
hypermetabolism
Rolandic operculum L −44 −2 2 4.39***
Insula lobe L −42 8 −14 3.61
Middle cingulate R 10 12 32 4.04
Middle cingulate L −4 2 40 3.98
Temporal pole R 42 18 −22 3.65
Fusiform R 40 −44 −16 3.62
Fusiform L −32 −46 −12 3.55
hypometabolism
No suprathreshold voxel
(B) ih vs. healthy controls
hypermetabolism
Insula lobe L −44 0 4 4.51***
Insula lobe L −44 8 2 4.50***
Insula lobe R 46 20 −2 3.44
Caudate nucleus R 6 12 −2 4.27**
Middle cingulate – −2 8 38 4.25**
Anterior cingulate – 0 48 16 4.16
Anterior cingulate R 6 38 28 4.02
hypometabolism
No suprathreshold voxel
Coordinates x, y, z refer to the standard Talairach and Tournoux (21) stereotactic space. 
Activation peaks’ significance is reported at the voxel-level, thresholded at punc ≤ 0.001, 
excepted ***pcorr < 0.05 and **trend pcorr < 0.06. Cluster extent is >50 voxels for all 
reported locations. Only the most representative voxels in each anatomical structure 
are displayed.
TaBle 1 | Demographic, clinical, and sleep characteristics of patients with narcolepsy type 1 (NT1), idiopathic hypersomnia (IH), and healthy controls.
nT1 ih controls p-Value
N = 16 N = 9 N = 19
N % n % n %
Sex
Male 12 75.00 2 22.22 16 84.21 0.003
Female 4 25.00 7 77.78 3 15.79
Age, in yearsa 30.00 (18.00–78.00) 27.00 (20.00–60.00) 36.00 (18.00–66.00) 0.84
BMI, in kg/m2a 23.80 (16.80–36.00) 24.32 (20.90–31.62) 0.40
Age at onset of EDS, in yearsa 17.50 (6.00–48.00) 17.00 (14.00–46.00) 0.70
Epworth sleepiness scalea 18.50 (13.00–22.00) 18.00 (11.00–24.00) 0.66
Hypnagogic hallucinations
No 6 37.50 5 55.56 0.43
Yes 10 62.50 4 44.44
Sleep paralysis
No 10 62.50 8 88.89 0.16
Yes 6 37.50 1 11.11
Multiple sleep latency test, in mna 4.50 (0.40–9.80) 10.00 (1.40–12.60) 0.02
Number of SOREMPSa 4.00 (2.00–5.00) 0.00 (0.00–1.00) <0.0001
aContinuous variables were expressed in median (minimum value–maximum value).
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higher glucose metabolism in narcolepsy than in IH in the right 
superior occipital gyrus, and conversely higher metabolism in IH 
than in narcolepsy in the bilateral middle orbital cortex and left 
supplementary motor area (Table 3; Figure 2).
Further analyses conducted at a more lenient and exploratory 
uncorrected statistical threshold (punc < 0.05) indicated further 
differences between populations. In narcolepsy as compared to 
IH, metabolism was higher in the middle occipital and temporal, 
fusiform, medial, middle and superior frontal regions, and the 
body of the caudate nucleus (Table  3; Figure  2). Conversely, 
metabolism was higher in IH than narcolepsy in a set of brain 
TaBle 3 | Statistical parametric mapping results of brain regions showing 
relative metabolism changes in patients with narcolepsy type 1 as compared to 
patients with idiopathic hypersomnia (IH).
hemisphere coordinates Z-score
(l)eft/(r)ight x y z
(a) narcolepsy vs. ih
Superior occipital R 30 −76 16 0.001**
Middle occipital L −32 −76 16 0.010
Fusiform R 34 −52 −10 0.014
Fusiform L −36 −34 −18 0.007
Supramarginal R 36 −44 30 0.024
Middle temporal L −46 −52 6 0.002
Caudate nucleus (body) L −20 20 16 0.037
Middle frontal L −32 16 66 0.005
Medial frontal L −12 −20 54 0.009
Superior frontal L −18 32 62 0.015
(B) ih vs narcolepsy
Middle orbital R 48 56 −6 3.39**
Middle orbital L −48 50 −2 3.26**
Supplementary motor area L −6 10 72 3.22**
Inf. frontal (pars triang.) L −52 18 4 2.42
Middle frontal R 34 6 56 1.88
Middle cingulate cortex – −4 −30 36 2.34
Inferior parietal L −54 −28 46 2.33
Inferior parietal R 54 −62 52 2.48
Angular gyrus R 56 −50 32 2.25
Angular gyrus L −38 −68 48 1.90
Precentral L −58 12 38 2.21
Precuneus R −6 −76 54 2.07
Postcentral L −16 −48 70 1.92
Caudate nucleus (head) R 10 10 2 2.06
Caudate nucleus (head) L −6 8 2 2.01
Cerebellum (tonsil) R 50 −60 −34 2.35
Cerebellum (pyramis) R 48 −72 −34 2.35
Cerebellar (culmen) – 0 −52 −24 2.22
Cerebellum (tuber) L −34 −78 −30 2.04
Cerebellum (tonsil) L −44 −54 −46 1.99
Coordinates x, y, z refer to the standard Talairach and Tournoux (21) stereotactic 
space. Activation peaks’ significance is reported at the voxel-level, thresholded at 
punc ≤ 0.05 (**punc < 0.001), uncorrected, with a cluster extent >50 voxels. Only the 
most representative voxels in each anatomical structure are displayed.
FigUre 2 | Higher (red) and lower (blue) regional cerebral glucose 
consumption in narcolepsy type 1 as compared to idiopathic hypersomnia, 
superimposed on a template T1-weighted magnetic resonance image. Higher 
metabolism (at punc < 0.001, cluster >50 voxels; see arrows) was found in 
narcolepsy in the superior occipital cortex (Occ) and lower metabolism was 
found bilaterally in the middle orbital gyrus (Orb) and in the supplementary 
motor area (not displayed). Other activations are displayed for the sake of 
completeness at punc < 0.05 uncorrected threshold, for clusters > 50 voxels.
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areas encompassing the middle orbital cortex bilaterally, the sup-
plementary motor area (SMA), the left pre- and post-central areas, 
the right precuneus, the inferior frontal and parietal regions, the 
angular gyrus, the cerebellum, and the head of the caudate nuclei, 
bilaterally (Table 3; Figure 2).
DiscUssiOn
We report here a case-control 18FDG-PET scan study in drug-free 
patients with NT1, IH, and healthy controls. Our results evidence 
hypermetabolism in the two pathological conditions as compared 
to healthy controls, which involves similar regions namely the 
anterior and middle cingulate and the insula that are constitutive 
of the salience cortical network (22, 23). No hypometabolism 
was found in patients as compared to controls. Additionally, we 
compared patient groups with narcolepsy and IH and found no 
significant results. At sub-statistical, we found higher metabolism 
in the superior occipital gyrus in narcolepsy, and higher metabo-
lism in the bilateral middle orbital cortex and left SMA in IH.
Functional MRI is the most commonly used method to iden-
tify resting-state brain networks. Alternatively, methods such 
as the FDG-PET may be useful to map resting brain functions 
while avoiding the temporospatial fluctuations inherent to the 
fMRI technique (24) and offering the injection and fixation of 
the radioisotope occurring outside of the scanner. Based on dis-
cordant PET-scan narcolepsy reports (2, 3, 6), we hypothesized 
that a large part of brain regional metabolism differences between 
patients with severe hypersomnia and healthy controls may actu-
ally reflect disturbances in the sleepiness-related neurocircuitry, 
that is, an alteration in the basic arousal system rather than a 
specific feature of the underlying disorder itself. Comparing 
well-characterized drug-free patients with NT1 and healthy 
controls, we showed in patients a significant hypermetabolism in 
a specific but widespread cortical network including the bilateral 
middle cingulate and fusiform regions, the rolandic operculum, 
and the temporal and insula lobes. These results confirm our 
preliminary findings in a limited sample of drug-free and treated 
patients with NT1 (2). A recent report also found that changes 
in brain metabolic activity in narcoleptic patients were positively 
correlated with results from the sleepiness scales and neuro-
cognitive performance tests (6). We found a similarly increased 
metabolism in patients with IH (as compared to controls) in the 
middle and anterior cingulate, bilateral insula regions, and in 
the caudate nucleus. These results constitute to our knowledge 
the first neuroimaging evidence for similarly altered regional 
cerebral metabolism during wakefulness in two distinct central 
6Dauvilliers et al. PET in Hypersomnias
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 350
hypersomnolence disorders, and the first neuroimaging study 
conducted in patients with IH.
The topography of increased metabolism identified in both 
narcolepsy and IH is closer to the salience cortical network than 
to the default-mode and the executive-mode networks. Indeed, 
we especially found hypermetabolism in the anterior cingulate 
cortex and insula, which are key regions in the salience network 
(7, 22). The finding of an involvement of the salience network 
in the context of the present investigation is in good agreement 
with its known functional role (23). The salience processing 
requires the integration of sensory, visceral, autonomic and 
attention systems throughout the brain, and initiates appro-
priate responses to key stimuli as a function of top–down 
attention and cognitive control processes (23, 24). The salience 
network is also though to subtend the maintenance of tonic 
alertness, with correlations between its activity and upper alpha 
band oscillations (25). Another study found a predominance 
of sympathetic-associated regions in salience-processing 
networks, whereas parasympathetic regions predominated in 
the default mode network (26). Recent evidence suggest that 
alterations within the salience network contribute to deficits 
in social, affective, attention, and cognitive control processing 
in neurological and neurodevelopmental disorders (24). Such 
alterations in central disorders of hypersomnolence may con-
tribute to a better understanding of the associated psychologi-
cal symptoms (27).
In resting-state fMRI studies, methods and instructions given 
to subjects may vary widely (e.g., eyes open, closed, gaze fixa-
tion) eventually resulting in functional connectivity differences 
(28). The investigation of brain functional imaging in drug-free 
patients with central hypersomnolence disorders requires a 
specific instruction to “resist sleeping” to avoid monoamine 
neurotransmission and synaptic activity changes secondary to 
daytime sleepiness per  se. All participants in the present study 
were scanned at rest but with similar instructions to not fall 
asleep during the PET procedure. The vigilance status during 
the scanning process may influence and raise some problems 
since subjects, especially drug-free patients affected with central 
hypersomnia, may present reduced attention and alertness 
leading to sleep onset. The increased metabolism identified in 
central hypersomnolence disorders close to the salience neural 
network reinforced its major role in the maintenance of the 
arousal level and the related sympathetic nervous system. This 
relative increased regional metabolism may thus be interpreted 
in this context as reflecting the patients’ motivation and cognitive 
effort to maintain alertness, as already reported in obstructive 
sleep apnea (29) and in Kleine–Levin syndromes (30). Sleep-
deprivation studies in normal controls reported that poor 
performance elicit an attentional recovery that may manifest 
as greater activation in main areas such as the prefrontal and 
cingulate regions (31). Indeed, emerging evidence suggests that 
alterations in the coupling of brain networks (i.e., default-mode 
and salience networks) might be critical in cognitive alterations 
reported after sleep deprivation (31, 32). The salience network 
may thus play an important role in initiating network switching as 
a function of sleep propensity underlying the “wake state instabil-
ity” model (33). A complex study using simultaneous fMRI-EEG 
recently investigated resting state brain function in adolescents 
with narcolepsy and showed altered brain dynamics that mainly 
relate to the default mode network (34).
Regional metabolic differences between the two patient 
groups were markedly restricted. In narcolepsy, there was 
increased metabolism in the middle occipital lobe (and to a 
lower extent in temporal, fusiform, medial, and superior frontal 
regions and the body of the caudate nucleus). In IH, increased 
metabolism was found in the middle orbital cortex and SMA 
(and to a lower extent in the pre- and post-central areas and the 
precuneus). The functional significance of these relative changes 
remains highly speculative, especially for areas where differences 
were found at lenient, unconventional statistical thresholds, and 
should be investigated in further studies. Notwithstanding, these 
findings may suggest an increased metabolism in several regions 
of the executive-control network in IH (35, 36). In contrast to 
patients with narcolepsy with often irresistible sleep as well as 
short and refreshing naps, patients with IH often complain of 
the non-refreshing quality of napping, sleep drunkenness, and 
persistent drowsiness (37). The metabolic differences between 
the two disorders within the executive-control network may 
be the signature of the abnormal neural system leading to the 
persistent sleep inertia, typical of IH. Our between-group finding 
differences may also indicate different modes of counteraction of 
hypersomnolence. Further works are required to validate the PET 
scan signature of sleep inertia, together with behavioral signs and 
EEG findings (38–40).
The present study has some strengths and limitations. Only 
typical and homogeneous drug-free patients with NT1 and IH 
were included and compared to healthy controls with similar 
instructions given during the scanning acquisition. While being 
fully awake during the whole process as controlled clinically and 
by video, unfortunately, the vigilance state was not monitored 
through EEG recording during the PET procedure. Our design 
procedure cannot directly affirm the absence of short change in 
alertness and even short sleep events during the whole scanning 
process. Further simultaneous EEG-monitored PET studies 
based on large samples are needed to confirm our preliminary 
results on IH, and to compare patients with central hypersomnia 
with healthy subjects in rested wakefulness and following a night 
of total sleep deprivation.
To conclude, we have evidenced a significant hypermetabolism 
in NT1 and IH in the wake resting state in regions constitutive of 
the salience cortical network, in comparison to healthy controls. 
The fluctuations of the brain’s intrinsic activity in both condi-
tions may reflect the vigilance status during the scanning process 
rather than the underlying deficient system. The current use of 
metabolic neuroimaging cannot yet contribute significantly to 
perform central hypersomnia diagnosis but may provide useful 
information regarding the resting organization of the brain dur-
ing drowsiness and sleep inertia.
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